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Abstract
The epidemic of HIV/AIDS linked to injecting drug usage is one of the most explosive in recent years. After a historical
epicentre in Europe, South and North America, at present it is clearly the main cause of dissemination of the epidemic
in Eastern Europe and some key Asian countries. Recently, 10 African countries reported the spread of HIV through
people who inject drugs (PWID), breaking one of the final geographical barriers to the globalization of the epidemic of
HIV among and from PWID.
Several countries of the Asia and Pacific Region have HIV epidemics that are driven by injecting drug usage. Harm
reduction interventions have been implemented in many countries and potential barriers to implementation are being
overcome. Harm reduction is no longer a marginal approach in the Region; instead, it is the core tool for responding to
the HIV/AIDS epidemic among PWID. The development of a comprehensive response in the Region has been
remarkable, including scaling up of needle and syringe programmes (NSPs), methadone maintenance treatment (MMT),
and care, support and treatment for PWID. This development is being followed up by strong ongoing changes in policies
and legislations. The main issue now is to enhance interventions to a level that can impact the epidemic.
The World Health Organization (WHO) is one of the leading UN agencies promoting harm reduction. Since the
establishment of the Global Programme on AIDS, WHO has been working towards an effective response to the HIV
epidemic among PWID. WHO's work is organized into a number of components: establishing an evidence base;
advocacy; development of normative standards, tools and guidelines; providing technical support to countries; ensuring
access to essential medicines, diagnostics and commodities; and mobilizing resources.
In this paper, we trace the course of development of the HIV/AIDS epidemic among and from PWID in the Western
Pacific and Asia Region (WPRO) as well as WHO's role in supporting the response in some of the key countries:
Cambodia, China, Lao PDR, Malaysia, the Philippines and Viet Nam.
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Background
Worldwide, around 13 million people inject drugs [1].
The first cases of HIV related to injecting drug use were
reported in the United States of America in 1982 in the
MMWR bulletin from the Centers for Disease Control and
Prevention (CDC), Atlanta [2]. As of September 1982,
13% of the AIDS cases in United States of America were
already people who inject drugs [2].
By the late 1980s and 1990s, concentrated epidemics of
HIV in PWID were restricted to North and South America
and Europe. Since the beginning of this century, explosive
epidemics of HIV have occurred among PWID in Eastern
Europe and in many countries of South, Central and
South-East Asia. Cases of HIV infection within the com-
munity of PWID were recently reported from 10 African
countries, disrupting the geographical barrier for a glo-
balized phenomenon [3].
Harm reduction is a new name for an old concept. One of
the first harm reduction activities was described in Great
Britain in 1926, when Sir Humphrey Rolleston, President
of the Royal College of Physicians, proposed the use of
morphine or heroin for the treatment of opium addiction.
This decision was the beginning of a pragmatic and
humanitarian approach to the treatment of drug addic-
tion [4].
In 1984, to control an outbreak of hepatitis B in the Neth-
erlands and pressured by the Association of Drug Addicts
(Junkies' Union), the health authorities of the City of
Amsterdam implemented one of the first known needle
exchange programme with a very successful outcome [5].
When the first cases of HIV transmitted by the sharing of
needles were recognized in 1985, the technology devel-
oped in Amsterdam was applied, again with good
results[5]. This approach has subsequently been proven to
be extremely effective in controlling HIV epidemics
among PWID [6-9].
The offer of treatment for drug dependence has proven to
be a very effective tool in controlling the HIV/AIDS epi-
demic arising from injecting drug use. From abstinence-
based treatment, to detoxification or self-support treat-
ment (such as Narcotics Anonymous), all these measures
have some impact on the epidemic [10]. However, substi-
tution therapy, in the case of opioids, is probably the most
effective and scientifically proven strategy to treat drug
dependence [10,11].
There is no published information on when methadone
was first used to treat heroin dependence. Apart from
reducing or eliminating illicit heroin and other drug use as
well as other benefits, methadone maintenance treatment
(MMT) reduces the level of involvement with crime asso-
ciated with opioid use [10,11]. Besides methadone, other
opioid substitution therapies (OSTs) are available such as
buprenorphine (both included in the WHO Model List of
Essential Drugs in 2005) [12].
Another important strategy to control the HIV/AIDS epi-
demic among PWID is the offer of antiretroviral therapy
(ART) for those in need [13-15]. A comprehensive pack-
age of harm reduction interventions (including needle
and syringe programmes [NSPs], substitution therapy
[ST], and care, support and treatment for PWID) is crucial
for controlling the HIV/AIDS epidemic and is being
implemented in many countries. It is now supported by
all UN agencies [16].
Since the establishment of the Global Programme on
AIDS, WHO has been working in a strategic and system-
atic way in the field of HIV/AIDS and drug use. WHO is
one of the leading UN agencies promoting harm reduc-
tion and the main interlocutor with the health system
involvement in harm reduction. Its work is organized into
a number of components: establishing an evidence base;
advocating for effective policies and programmes; devel-
oping normative standards, tools and guidelines; support-
ing countries in implementing programmes; ensuring
access to essential medicines (such as methadone and
buprenorphine), diagnostics and commodities; and
mobilizing resources [17]. The Organization has officers
working on harm reduction in almost all the WHO
Regions who focus on controlling epidemics caused by
injecting drug use. In principle resolutions are based on
available evidence and backed by science and experts
opinions, but as a multilateral organization there are also
political elements that can influence on the decision mak-
ing process.
The Western Pacific and Asia Regions
Although national HIV prevalence levels are still very low
in the Asia-Pacific region, the huge population sizes of
many Asian countries mean that very large absolute num-
bers of people are being infected each year with HIV [18].
Urgent responses are required; effective responses in some
areas of the epidemic by countries such as Thailand and
Cambodia have shown how much can be done [19,20].
Unlike in Africa, the Asian epidemics are concentrated in
identifiable high-risk groups (primarily those involving
PWID who share needles, sex workers and men who have
sex with men). Hence, HIV in the Asia region could be
controlled if these high-risk groups are targeted with spe-
cific interventions [21,22].
Many countries in the Asia-Pacific region face difficult
public policy and legislative problems with regard to sex
work, homosexuality and drug use. In addition, wide-
spread poverty, and a general lack of access to effectiveHarm Reduction Journal 2008, 5:26 http://www.harmreductionjournal.com/content/5/1/26
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health-care services by the poor and disadvantaged in
both rural and urban areas means that the challenges of
developing targeted intervention programmes, and ensur-
ing coverage of vulnerable groups, are particularly acute
[20].
The WHO Western Pacific Region comprises 37 countries
from the Mekong River Valley in Asia to countries in the
Pacific. Many of the epidemics in the Region are currently
driven by needle-sharing among PWID. The epidemic of
HIV is clearly driven by injecting drug use in three of the
countries (China, Malaysia and Viet Nam). China
accounts for 75% of the total population of the Region.
Three other countries in the Region are beginning to build
a comprehensive response to limit the burden of the HIV
epidemic related to injecting drug use (Cambodia, Lao
PDR and the Philippines). The other 31 countries are con-
sidered very Low Prevalence countries (with the exception
of Papua New Guinea considered as the only country in
the region with a generalized epidemic, but with a clear
sexually transmitted epidemic). In the present paper we
concentrate the information in the 6 key countries for the
subject.
Cambodia
The epidemic in Cambodia
The first case of HIV infection was notified in Cambodia
in 1991. By 2003, approximately 123,000 people were liv-
ing with HIV including 57,000 women and 9,000 chil-
dren out of a total population of 14,071,000 [23,24]. An
estimated 19,800 adults had developed AIDS by 2005
[25].
National prevalence of HIV among those aged 15–49
years has declined from 1.2% in 2003 to 0.9% in 2006
[26] with HIV transmission occurring primarily through
sexual contact [23]. In June 2007, HIV sentinel surveil-
lance (HSS)-based data from the Center for HIV/AIDS/
Dermatology/STIs (NCHADS) revealed that in 2006 the
number of people living with HIV/AIDS (PLHA) was
approximately 67,200, showing that the number of PLHA
has decreased over time [26].
In 2004, about 20,000 people were using amphetamine-
type stimulants (ATS) and 2,500 were heroin users, of
whom 1,750 might have been PWID [27]. Local non-
governmental organization (NGO) reports using small
sample sizes put the HIV prevalence among PWID in the
capital, Phnom Penh, at around 15%, and of ATS users at
around 5% or less [28]. Knowledge of HIV transmission
through shared needles/syringes is poor among PWID
[29]. Consequently, patterns of the epidemic seem to be
changing from one driven by sexual contact to one mixed
with injecting drug use.
Response to the epidemic in Cambodia
Cambodia developed a policy for mounting a strategic
response to harm reduction in 2003. The HIV/AIDS
National Strategic Plan of the National AIDS Authority
(NAA) explicitly promotes harm reduction as an evidence-
based intervention [30]. The drug control master plan for
Cambodia, developed by the National Authority for Com-
bating Drugs (NACD), refers to the need to implement a
comprehensive approach to HIV/AIDS [31].
A memorandum of understanding (MoU) was signed
between the NACD and NAA in 2004 to collaborate in
preventing drug-related HIV/AIDS. An illicit drug-related
HIV and AIDS working group (DHAWG) was then estab-
lished to integrate HIV/AIDS into the full range of illicit
drug-related activities nationwide and now meets quar-
terly.
Capacity building for harm reduction has been under-
taken of several provincial NGOs and Government social
service agencies. Two local NGOs in Phnom Penh have
been operating comprehensive harm reduction commu-
nity outreach and drop-in centre activities – including
NSPs – under NACD authorization since 2005. Cambodia
now has at least 11 centres for the treatment and rehabil-
itation of drug users located around the country [32].
However, service capacity in all such centres is extremely
limited according to Multi Agencies Rapid Assessment of
treatment and rehabilitation centres in Cambodia.
Phnom Penh conducted in December of 2007 [unpub-
lished]. Minimum standards for such centres have now
been drafted for Government approval.
In 2008, the Government announced its intention to
establish a methadone maintenance programme in
Phnom Penh (document N° DG-DHS). Planned for Sep-
tember 2008, referrals will be established to services for
voluntary counselling and testing (VCT), sexually trans-
mitted infections (STIs) and tuberculosis (TB), prophy-
laxis and treatment of opportunistic infections (OIs)/ART
as well as emergency medical assistance. NCHADS is also
developing detailed plans to establish several VCT dem-
onstration sites in the capital to attract drug users; this
approach will then be scaled up nationwide. In 2008,
NCHADS also plans to commence referral for prisoners to
VCT, and drug treatment and rehabilitation centres
nationwide.
The role of WHO in Cambodia
Since its support to a qualitative assessment of drug use in
2004 in collaboration with the US CDC, WHO in Cambo-
dia has become the co-lead agency with the United
Nations Office on Drugs and Crime (UNODC) for drug
use in the Joint UN Theme Group on HIV/AIDS [33].
WHO's work includes technical assistance to develop andHarm Reduction Journal 2008, 5:26 http://www.harmreductionjournal.com/content/5/1/26
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implement a continuum of care for drug users in all set-
tings in Cambodia using evidence-based international
good practices.
In collaboration with a range of partners, WHO (i) pro-
vides support for the operationalization of the DHAWG
and associated costed National Strategic Plan for Drug
Use and HIV/AIDS; (ii) provides technical assistance for
the NSP policy, guidelines, standard operating procedures
(SOPs) and implementation plan (with related training in
2006); (iii) provides technical support to establish an
MMT programme; (iv) gives technical advice for the devel-
opment of policies, guidelines and SOPs related to drug
dependency detoxification and treatment, and related
resource mobilization for both community and closed
settings; (v) supports linkages between the NACD,
NCHADS, National Programme for Mental Health
(NPMH) and NGOs working with drug-using communi-
ties for an effective response to the epidemic; (vi) supports
communication initiatives including the development of
guidelines in the Khmer language targeting health, social
and education service providers, law enforcement person-
nel and parents, as well as four harm reduction video edu-
cational interventions for PWID, entertainment workers,
ATS users and inhalant/solvent users; (vii) provides tech-
nical assistance to the Government and its NGO partners
for resource mobilization, such as the Global Fund and
the Swedish International Development Agency (SIDA).
China
The epidemic
China sits between the "Golden Triangle" and "Golden
Crescent" – two of the three biggest opiate suppliers in the
world – and has seen a significant surge in the number of
illicit drug users since the 1980s. Heroin is the main illicit
drug used in China, with amphetamine and polydrug use
on the rise.
China's first case of HIV was reported in 1985 and first
case due to injecting drug use in 1989 [34]. By December
2007, there were an estimated 700,000 PLHA in China
[35]. The national HIV prevalence is 0.05% (range 0.04%
to 0.07%) [36]. Prevalence among PWID increased from
1.95% in 1996 to 6.48% in 2004, and is rising and spread-
ing from these groups to the general population [36].
PWID continue to engage in high-risk behaviours.
Recently published national surveillance data show that
40% of participating PWID reported needle-sharing [35].
Estimated data indicate a focused spread of HIV infection
among PWID. At the end of 2005, there were about
288,000 drug users living with HIV/AIDS, accounting for
44.3% of the total estimated HIV cases [37]. The epidemic
is concentrated in Yunnan, Xinjiang, Guangxi, Guang-
dong, Guizhou, Sichuan and Hunan provinces, with each
province having an HIV prevalence of more than 5%
among PWID and over 10,000 HIV-positive PWID.
Together, they account for 89.5% of all people infected
through injecting drug use[36]. As of 30 December 2005,
1.16 million drug users were registered with the Ministry
of Public Security (MPS) [37].
Response to the epidemic in China
The unique pattern of the HIV/AIDS epidemic in China –
high HIV infection rate among PWID and former plasma
donors (FPDs), but a relatively low overall infection rate
in the country – provides a window period for taking
action [38]. China has achieved remarkable national
progress in its comprehensive response to HIV/AIDS. The
first and second five-year Action Plans (2001–2005 and
2006–2010) were formulated; the second aimed to cover
no less than 90% of most-at-risk populations and vulner-
able migrants with effective prevention interventions. By
2010, drug maintenance treatment clinics should be set
up to provide services for no less than 70% of opium users
(mainly heroin users) in counties and cities with more
than 500 registered drug users. No less than 50% of PWID
in the areas implementing NSPs should be provided with
clean needles and syringes[39]. In 2006, the State Council
issued the AIDS Prevention and Treatment Regulations
that include promotion of programmes for drug users
such as drug-maintenance treatment and other effective
interventions [40]. Although the regulation does not
explicitly mention needle exchange programmes, imple-
mentation of the approach in 775 sites in 17 provinces
indicates the endorsement of this approach in the country
[39].
In February 2003, the Ministry of Health (MOH), MPS
and the State Food and Drug Administration (SFDA)
issued an interim "Opium abusers community-based
drug maintenance treatment protocol" to start piloting
MMT [41]. In July 2006, the three agencies revised the
protocol to support expansion of the MMT programme in
22 provinces [42].
A 2007 evaluation survey conducted in the first phase of
eight MMT clinics found a positive change in the self-
reported rate of injecting drug use, drug-related illegal
offences, employment opportunities and family relations
[35]. The average frequency of drug injection declined
from 90 to two times per month and self-reported crimi-
nal behaviours reduced from 20.7% to about 3.8% [43].
Entry requirements deterred many people from accessing
the services, especially migrants and others without the
required documents [39]. In 2006, the Government made
adjustments to methadone delivery, such as permitting
access to methadone clinics anywhere, linkages to other
services, mobile methadone provision and waiving of res-
idency documents [39].Harm Reduction Journal 2008, 5:26 http://www.harmreductionjournal.com/content/5/1/26
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By December 2007, China had 503 functional MMT clin-
ics. Cumulatively, over 97,554 drug users had entered the
programme. In addition, 45,121 PWID had regularly
attended NSPs [44]. These clinics regularly provide free
HIV testing and counselling services to all who join the
MMT programme. China has set a target of operating
around 700 MMT clinics by the end of 2008 [44].
The Chinese government has taken bold steps to scale up
HIV testing and counselling, offer free ART to AIDS
patients, and expand primary prevention measures such
as MMT and NSPs for drug users, and condom promotion
for sex workers and men who have sex with men (MSM).
The remarkable achievements in such a short period of
time indicate that China is strongly committed to limiting
the epidemic and maintaining a low HIV prevalence in the
future [38].
Although the current policy environment is favourable for
harm reduction activities, China faces several difficult
challenges in establishing a comprehensive HIV/AIDS
response among PWID. These include (i) difficulty in
coordination among different bodies; (ii) inadequate
implementation of prevention strategies; (iii) increasing
the demand for care, support and treatment for PWID to
reach all those in need; and (iv) need for effective control
of HIV/AIDS transmission inside closed settings.
In China, eligible HIV-positive PWID in the community
have access to free ART since 2003 through referral link-
ages between MMT clinics, hospitals and CDC in China.
Over 31 000 adult and paediatric patients have been
treated [45]. China is also piloting ART in prisons in
Guangxi, Yunan, Sichuan and Hunan. Prisoners on ART
are mainly drug users.
The role of WHO in China
WHO assists China to confront the challenges it faces, by
providing timely information about new approaches and
technologies that are later adapted and adopted according
to China's needs. WHO works with several key partners
on various issues through the UN Theme Group on HIV/
AIDS and Drug Use.
Specifically, WHO supports China in the following areas:
(i) policy development and advocacy (e.g. supporting
pilot NSP and MMT projects); (ii) providing HIV preven-
tion education; (iii) training staff in drug detoxification
and drug dependence treatment in closed settings; (iv)
providing technical support for the provision of drug
dependence treatment from pilot projects to scaling up;
(v) advocacy for testing and counselling; (vi) care, support
and treatment for PWID; and (vii) monitoring and evalu-
ation of harm reduction projects.
WHO is also working with the Government to change the
common perception that drug users are criminals instead
of people who are ill and in need of care, support and
treatment.
Lao PDR
The epidemic
Lao PDR is experiencing an impressive development in
the recent years. According to UNAIDS Report of 2008,
Lao PDR is currently losing the status of a considered
land-locked country and being fast transformed in a land
linked country [46]. A high way being developed by the
Asian Development Bank and the Great Mekong Sub-
Region Governments (the Mekong Highway Project) is
faster optimizing the mobility of the population and the
development of the entertainment industry [47].
Lao PDR is a low HIV-prevalence country. To date, the
HIV epidemic has been driven by multipartner client-sex
worker behaviours, with some data showing that HIV
infection may spread as well among MSM [46]. It is esti-
mated that 3700 people are living with HIV in the coun-
try, which has a population of 5,924,000. The estimated
prevalence is around 0.1% among the 15–49 years' age
group [48].
Lao PDR has Myanmar, China (Yunnan), Viet Nam, Thai-
land and Cambodia as its neighbours and injecting drug
use has been reported in all these countries. Lao PDR is in
the border of the Golden Triangle which is one of the
important sources of opium globally speaking. Lao PDR is
also a neighbor of countries that are producing metham-
phetamines and is therefore being considered as a transit
country for methamphetamine and its precursors [46].
The traditional use of opium is still the main drug used in
Lao PDR but there are increased reports in the use of
methamphetamines and injection of opium and this
trend seems to be a recent phenomenon. The national
behavioural surveillance survey (BSS) done in 2001 did
not indicate any injecting drug use among the sample
[49]. The second round of BSS in 2004 indicated that up
to 11% of sex workers in one province indicated that they
had ever injected drugs[50]. Anecdotal evidence shows
that injecting drug use is becoming more common,
though the HIV epidemic has not yet clearly started
among PWID.
Response to the epidemic in Lao PDR
The response to the HIV/AIDS epidemic in Lao PDR
started early and has a high level of public commitment.
Lao PDR developed a National Strategy and Action Plan
2006–2010, with clear priority targets. A costed action
plan forms the basis for the resource mobilization of the
country. According to UNAIDS 99.52% of the funds
comes from external resources [46]. Global Fund round 6Harm Reduction Journal 2008, 5:26 http://www.harmreductionjournal.com/content/5/1/26
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is one of the important sources of funds to support the
response to the epidemic in Lao, which also has funds
from USAID, AusAID, SIDA, among others. It is important
to notice that Lao PDR included its action plan for HIV/
AIDS in their 6th National Socio-Economic Development
Plan, elevating the fight against the epidemic for a higher
level of development concerns of the country [46].
Recently, with the support of the UN system, the Lao PDR
Government set up a Task Force on HIV and Drug Use
with the objectives of developing a policy, proposing con-
crete activities to address the vulnerability of drug users to
HIV, and developing guidelines for harm reduction and
treatment of drug abuse [51]. This Task Force is jointly
chaired by the Lao PDR National Commission for Drug
Control and Supervision, and the Ministry of Health, and
is composed of different stakeholders enlarging the partic-
ipation of many different sectors in the response of the
HIV/AIDS Epidemics.
Harm reduction for PWID is embedded in the National
HIV/AIDS/STI Strategy 2006–2010 [52]. This includes
providing a supportive environment for PWID (advocacy,
legal and policy framework, review and update of the
national policy) and providing PWID with the means to
protect themselves from the consequences of drug use, as
well as scaling up towards universal access. So far the
harm reduction activities are very incipient in the country
and rely on outreach work.
An access to ART project was started in 2003, which at the
moment covers around 700 patients in two centres of the
country. Even if a larger number of people are in need of
ART according to estimates, there are no known people in
need of ART who are not receiving it. According to the
Universal Access Report launched by WHO, UNAIDS and
UNICEF in June of 2008, Lao PDR is one of the few coun-
tries in the world where the coverage for people in need of
ARV bounds 100% [53].
The role of WHO in Lao PDR
WHO supports the Task Force technically (with UNODC
and UNAIDS) and financially by strengthening coordina-
tion, carrying out a rapid assessment of the injecting drug
use situation, organizing study tours, developing and
adapting guidelines for the treatment of addiction, organ-
izing advocacy workshops and supporting the secretariat
of the Task Force.
The main partnership of WHO in the country is with the
Sweden Cooperation for a 2 years project (2008/2009)
specifically dedicated to the implementation of Harm
Reduction as a key strategy to avoid or mitigate the epi-
demic in Lao PDR.
As Lao PDR does not yet have an HIV epidemic caused by
injecting drug use, this gives the country the opportunity
to start a meaningful harm reduction programme and
thereafter try to prevent an epidemic.
Malaysia
The epidemic
The first case of HIV was diagnosed in Malaysia in 1986
[54]. By December 2007, the estimated number of PLHA
in Malaysia was 69,000 out of a total population of
25,347,000 [55]. The majority of reported cases were in
the age group of 20–39 years, the younger and potentially
more productive segment of the country's population.
During the same period, there were 76,389 reported HIV
infections of which 70,300 were in males and 6089 in
females (cumulative); 73.7% of HIV infections occurred
among PWID [56].
As a consequence of the large proportion of PWID in the
population with HIV/AIDS, the epidemic in Malaysia is
clearly a concentrated epidemic, since HIV prevalence has
been less than 1% among the general population but con-
sistently higher than 5% (between 3% and 20%) in PWID
[57]. The first round of the national BSS conducted during
2003–2004 showed a high frequency of sharing injecting
equipment among PWID (71.5%) [55]. Males account for
more than 90% of the reported cases; however, the epi-
demic is rapidly advancing among females [55,56]. The
proportion of reported HIV infections transmitted
through homo/bisexual and heterosexual contacts is also
increasing [55]. There is a high level of prevalence in spe-
cific populations and certain regions, as more than 10% of
commercial sex workers in Kuala Lumpur were found to
be positive for HIV in a study conducted in the year 2000.
Response to the epidemic in Malaysia
From a highly punitive approach of sending drug users to
forced treatment centers as the only strategy by the begin-
ning, the response to the HIV/AIDS epidemic in Malaysia
has been stepped up in the past 18 months [58]. Respon-
sibility for drug treatment rests since 2006 with the Minis-
try of Health, and Malaysia's National Strategic Plan on
HIV/AIDS for 2006–2010 includes calls for methadone
and buprenorphine, needle exchange and free ART [59].
Malaysia now has six NSPs coordinated by the Malaysian
AIDS Council (MAC) [58]. These projects handle more
than twice the expected number of clients. At the end of
2007, 3600 PWID had been reached by NSPs [58]. A tar-
get has been set of reaching 20,000 PWID by 2010 [58].
MMT has been scaled up continuously since it was intro-
duced in October 2005. The country now has 74 MMT
services serving more than 4000 PWID. As of 31 Decem-
ber 2007, a total of 4,135 drug addicts had been registered
and enrolled into the Government MMT programme,Harm Reduction Journal 2008, 5:26 http://www.harmreductionjournal.com/content/5/1/26
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which is totally free for patients. Furthermore, the expan-
sion of methadone availability in Malaysia is being also
amplified by the inclusion of General Practitioners. In
April 2008, the MMT programme was extended into the
prison system starting with a pilot project in Pengkalan
Chepa prison in one of the eastern states. Methadone
availability is being enhanced and monitored by the Min-
istry of Health. The cost has been reduced several fold, but
qualified counsellors are scarce [58].
At present, 40% of those who fulfill the criteria for initiat-
ing ART are under treatment (personal communication,
Dr Christopher KC Lee, during the WHO symposium on
Drug use and HIV in Kuala Lumpur, Malaysia, 3 Decem-
ber 2007). This is a great development in comparison
with 10% 18 months ago (personal communication, Dr
Christopher KC Lee, during the WHO symposium on
Drug use and HIV in Kuala Lumpur, Malaysia, 3 Decem-
ber 2007). However, Malaysia still needs to develop the
sexual component of its response to the HIV/AIDS epi-
demic due to the rapid spread among the female popula-
tion.
The role of WHO in Malaysia
WHO has been constantly and consistently providing
technical support for capacity building. The first contribu-
tion to the Government of Malaysia in this field was in
2004 when an Injecting Drug User Behaviour Survey
Study was conducted with technical and financial support
from WHO. This study was a baseline for a series of deci-
sions that the Government took to better develop its strat-
egy to confront the epidemic.
In September 2004, a workshop on the development of
the National Strategic Plan on HIV/AIDS was conducted,
again with WHO support. The Plan was developed in the
workshop itself and the first draft was designed by a WHO
consultant to support the Government of Malaysia. This
strategy was later reviewed in 2005, also with WHO sup-
port, when the Government of Malaysia presented their
evaluation of the Millennium Development Goals
(MDGs) and regretted that the only goal that Malaysia did
not achieve at that point in time was MDG 6 – failure to
control HIV/AIDS.
Again in 2005, in conjunction with the Asian Parliamen-
tarian Forum, WHO supported a dialogue in the Malay-
sian Parliament advocating for their support to harm
reduction. This activity brought about strong political
support for harm reduction.
In 2006, WHO conducted a Bi-Regional Workshop
(WPRO and SEARO) in Malaysia and an Informal Consul-
tation to develop guidance for care, support and treatment
for PWID. This was crucial for developing the next step of
engaging PWID in treatment with ARVs.
Technical support was also provided for the monitoring
and evaluation exercises associated with the pilot NSP and
MMT programmes. WHO Malaysia hired highly respected
international consultants to help conduct an in-depth
analysis of the MMT as well as NSP programmes. There
was no seminar or event in that field where WHO was not
clearly involved.
WHO also supported a Rapid Assessment Study among
PWID; and their initial findings were presented during the
Symposium on Drug use and HIV in Kula Lumpur, Malay-
sia, held on 3 December 2007. The study concluded that
the majority of subjects initiated drug use before the age
of 18 years and shift to injecting very fast. Heroin is the
main drug of injection; however, an increasing number of
people use ATS as their main drug of choice. Rates of shar-
ing of injection equipment are very high and condom use
is less than 20% with all kinds of partners. The data will
be released in 2008 by WHO and the University of Sains,
Malaysia.
The country's response to the HIV/AIDS epidemic among
PWID was analysed in depth at a national AIDS confer-
ence and a national symposium on Drug use and HIV pro-
moted by WHO and partners in December 2007. The
achievements were acknowledged both within and out-
side Malaysia. Malaysia's understanding of its epidemic
pattern is increasing based on evidence, and the country is
stepping up its response by scaling up methadone clinics,
NSPs, as well as care, support and treatment for PWID.
At present, besides ongoing technical assistance, WHO is
providing support for policy development in the area of
Government and public acceptance of harm reduction
programmes.
The Philippines
The epidemic
The HIV epidemic in the country has been described as
low prevalence [60]. There were 7,490 people estimated
to be living with HIV in 2007, out of an adult population
of 44,608,300 (15–49 years old), with an HIV prevalence
rate of 0.017%. HIV in the Philippines is predominantly
sexually transmitted (85%) [60].
However, drivers of the epidemic in PWID have been doc-
umented. In 2007, an integrated HIV behavioural and
serological surveillance (IHBSS) showed that 52% of
PWID had shared needles and syringes the last time they
injected; condom use was only 24%; and prevalence of
hepatitis C among PWID was 88% in Cebu City and 6%Harm Reduction Journal 2008, 5:26 http://www.harmreductionjournal.com/content/5/1/26
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in Zamboanga City [61]. At present, there are about
9,984–20,316 PWID in the country [62].
The National HIV and AIDS Registry, a passive form of
surveillance, recorded a total of 3,061 reported cases of
HIV from January 1984 to December 2007, of whom 7
were PWID [62].
Response to the epidemic in the Philippines
The Department of Health (DOH), as chair of the Philip-
pine National AIDS Council, a multisectoral policy-mak-
ing body on HIV prevention, is the lead government
agency mounting a national response to the HIV epi-
demic. The country's responses are geared towards univer-
sal access to prevention, treatment, care and support,
including protecting the rights of PLHA and their families
[63].
The following prevention strategies are being imple-
mented: community outreach and education, scaling-up
counselling and testing, early diagnosis and management
of STIs, 100% condom use programme (15 sites), preven-
tion of mother-to-child transmission (PMTCT, pilot
implementation), provision of post-exposure prophy-
laxis, and a harm reduction programme for PWID (3 sites)
[64].
Implementing a harm reduction programme in the Phil-
ippines is challenging because of the illegal nature of drug
use. Despite a law on the prevention and control of AIDS
(Republic Act 8504), a more recent law, the Dangerous
Drugs Act (Republic Act 9165) emphasizes the supply and
demand reduction approach to control drugs. Recogniz-
ing these conflicting mandates, the National AIDS STI Pre-
vention and Control Programme and the Philippine
National AIDS Council (PNAC) Secretariat initiated dis-
cussions with the Dangerous Drugs Board, the Philippine
Drug Enforcement Agency, and other relevant partners, to
come up with more appropriate and acceptable
approaches that would treat the PWID situation in the
country as a public health concern to be addressed rather
than as a criminalized, legal issue.
While central government agencies tried to work at the
policy level, NGOs, in coordination with the local health
departments and local stakeholders, started providing
harm reduction services among PWID including commu-
nity outreach, peer education, referral networking to
counselling, provision of clean needles and syringes, psy-
chosocial support, and referral and treatment for STIs and
other health-related concerns. Outreach work was initi-
ated in 1995 by the Program for Appropriate Technology
in Health (PATH) in partnership with the University of
Southern Philippines Foundation, through the AIDS Sur-
veillance and Education Project of USAID. Other NGOs
such as Remedios AIDS Foundation, KABALIKAT, USAID-
Local Enhancement and Development (LEAD) for Health
Project were also involved in outreach education work
among PWID. Currently, the Philippine NGO Council for
Population, Health and Welfare, Inc. and the Tropical
Disease Foundation continue to implement PWID harm
reduction programmes through the Global Fund AIDS
projects.
In 2007, the Asian Development Bank's Regional Techni-
cal Assistance Project complemented the country's initia-
tives by supporting the conduct of a situation and
response analysis of PWID-related work in the country
and of IHBSS among PWID in the cities of Zamboanga
and General Santos [65].
Currently, 800 PWID are reached by prevention services
through three major outreach service delivery points,
which includes provision of clean needles/syringes
[64,66,67].
In the area of care and support, there are 11 treatment
hubs with trained HIV AIDS Core Teams that provide clin-
ical and psychosocial care and support to PLHA. ART is
provided free since 2005. The baseline CD4 count is also
done free at the STI AIDS Cooperative Central Laboratory
(funding support from Global Fund). As of December
2007, there are 390 PLHA enrolled for free ART and are
receiving extended care and support services [64].
Role of WHO
WHO remains the major provider of assistance to the
DOH in advocating for sustained efforts to support the
harm reduction programme among PWID and to dispel
the perception that this is not effective and not needed in
the Philippines. WHO is the lead agency on matters per-
taining to health, and in preventing the transmission of
HIV through injecting drug use (since there is no UNODC
office in the Philippines). In conjunction with other UN
agencies, WHO supports the evidence-based development
of harm reduction strategies and ensures that only scien-
tifically effective harm reduction strategies are introduced,
adapted and continuously implemented in the Philip-
pines in order to address the public health concerns of
people who inject drugs.
WHO supported a study on behaviour patterns among
PWID admitted to rehabilitation centres; the results were
initially disseminated in January 2008. WHO also con-
ducted the first orientation on PWID harm reduction pro-
gramme (2007) among DOH and UN staff, and among
high-level officials of the DOH, Department of Interior
and Local Government, and the PNAC Secretariat. WHO
is a key member of the Harm Reduction Working GroupHarm Reduction Journal 2008, 5:26 http://www.harmreductionjournal.com/content/5/1/26
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which will draft appropriate national guidelines on the
harm reduction programme in the Philippines.
Viet Nam
The epidemic
After the first HIV case was diagnosed in 1990, transmis-
sion and reporting of cases accelerated such that it was
estimated that there were 293,000 PLHA in Viet Nam at
the end of 2007 [68]. Cumulative reporting up to end of
December 2007 documented 156,210 HIV infections;
62,145 cases of AIDS and 34,476 deaths due to AIDS [69].
The majority of the reported cases (83.16%) were aged
between 20 and 39 years; 57.28% of the total were
between 13 and 29 years; 82.77% of cases were male and
prevalence among women was slowly increasing [68].
Estimated adult HIV prevalence is 0.5% [70].
Since 1990, the majority of reported HIV infections and
AIDS cases have been in PWID (50–60%), though hetero-
sexual transmission, particularly through commercial sex,
appears to be increasing [69]. With a low prevalence of
HIV in the general population and high prevalence in
PWID (28.6% nationally), the HIV epidemic remains
"concentrated" [68]. In the Viet Nam Integrated Behav-
ioural and Biological Surveillance Survey of 2005–2006,
around one third of PWID reported sharing of syringes in
the previous six months and more than 50% reported
unprotected sex with sex workers [71].
Response to the epidemic in Viet Nam
The Ministry of Health (MoH) is the lead agency for harm
reduction activities. HIV prevention measures were initi-
ated in 1993 and predominantly involved mass education
and small-scale needle/syringe distribution. In 2003, the
first of the large donor-funded prevention projects started
with financial support from the UK Department for Inter-
national Development (DFID) and Norwegian Directo-
rate for Development Cooperation (Norad) in 19
provinces and two cities (initially under MoH-WHO co-
managment, later by MoH with technical assistance from
WHO). In 2005, the response was expanded by the addi-
tion of the World Bank-funded MoH Viet Nam HIV/AIDS
Prevention Project in 18 provinces and two cities (six
provinces and the two cities overlap) [72].
An impressive government HIV/AIDS response over the
past five years has seen an expanding public health
response and the National Assembly pass the Law on HIV/
AIDS Prevention and Control in 2006 and associated
Decree 108/2007 ND-CP in 2007 [73,74]. Protracted and
careful advocacy on the part of the Communist Party
Commissions, local NGOs, international community
members and dedicated National Assembly members
facilitated passage of the 2006 Law.
Under the Law, the MoH is specifically mandated to lead
harm reduction activities for HIV prevention among risk
groups and to work with the Ministry of Public Security
(MoPS) and Ministry of Labour, Invalids and Social
Affairs (MoLISA) to ensure the implementation of needle
and syringe, condom distribution and OST programmes.
The MoH Viet Nam Administration of HIV/AIDS Control
(VAAC)-led projects for prevention have expanded since
the HIV/AIDS Law, in particular, coverage with NSPs
increased from 21 provinces in 2005 to 42 provinces in
2007. During 2007, expansion of all projects led to the
distribution by government health services of more than
11 million needles and syringes (sufficient to provide
around one quarter of the registered PWID with one per
day), and more than 100 million condoms – predomi-
nantly through the activities of more than one thousand
peer outreach workers [75,76].
In 2007, VAAC, in collaboration with other MoH depart-
ments and international partners, developed national
guidelines and a proposal for pilot MMT programmes for
1500 patients. Treatment commenced at three sites each
in Hai Phong and Ho Chi Minh City during the first half
of 2008 with support from the US Government Presi-
dent's Emergency Plan for AIDS Relief (PEPFAR), WHO,
DFID and World Bank [77].
By the end of September 2007, a total of 14,180 adults
were receiving ART in 64 provinces – a 5.7-fold increase
from the end of 2005 (or 28.4% of those needing ART)
[69]. Though the proportion of ART patients who are
former or active PWID is unclear, scaling up of ART cre-
ated opportunities for direct collaboration between health
staff and PLHA support groups whose risk behaviour had
previously marginalized them. This was important for
mobilization of appropriate peer workers for outreach in
harm reduction.
The national network has more than 80 Treatment and
Education Centres, which are institutions for drug users
(and sex workers) who are required to go through drug
detoxification, education and occupational training for
one to two years (except in Ho Chi Minh City which has a
five-year requirement). Implementation of small-scale
provision of ART commenced this network in 2007 with
PEPFAR support. Substantial expansion is planned under
the Global Fund Programme in 2008 and beyond. Many
of these closed settings, housing over 60,000 drug users,
have a high prevalence of HIV (30–60%) and burden of
AIDS-related illnesses, but until now have been without
adequate resources to provide HIV prevention, treatment
or care [69].Harm Reduction Journal 2008, 5:26 http://www.harmreductionjournal.com/content/5/1/26
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The role of WHO in Viet Nam
In response to requests from the MoH, WHO has been a
principal provider of technical assistance for harm reduc-
tion activities, which are largely conducted by the health
sector. WHO efforts to increase the coverage and quality
of harm reduction interventions for the MoH-DFID/
Norad-funded HIV prevention project in 21 provinces has
been through the development of guidance documents,
tools, identification of good practices for the needle-
syringe and condom programmes for entertainment
establishments, street-based sex workers and other groups
at risk through non-pharmacy outlets, and capacity build-
ing, including participatory training for managers and
peer outreach workers.
Building on these experiences, WHO has been taking a
lead role in supporting VAAC, with support from DFID
and SIDA, to develop the national technical guidelines on
the needle-syringe and condom programmes, in collabo-
ration with PEPFAR, UNAIDS, UNODC and others. Fur-
thermore, development of strategic and operational
collaboration between MOH, MOLISA, MOPS and their
local entities are being promoted and supported by Joint
UN Team on HIV in which WHO plays an active role.
Through 2007, WHO and international partners sup-
ported the complex collaborative development process
for the MMT guidelines, implementation proposal, train-
ing curriculum and methadone procurement.
WHO provided key support to OST/NSP study tours for
the MoH in 2007 to sites in Hong Kong, Malaysia, Indo-
nesia and Australia, including participation to provide
translation into a familiar language and organizational
context. WHO continues to collaborate with UNODC and
UNAIDS to ensure that partnerships between the MoH
and MoPS/MoLISA remain supportive of harm reduction.
WHO has continued to support expansion of HIV treat-
ment and care including ART for active PWID and devel-
opment of the National HIV Monitoring and Evaluation
Framework including refinement of indicators related to
PWID and Sex Work.
Challenges remain for WHO, working with advocacy part-
ners, to expand the supportive political environment for
harm reduction in Viet Nam and in the development of
effective HIV prevention and care linkages between closed
settings ('Treatment and Education' centres/prisons) and
communities.
WHO Regional Office for the Western Pacific (WPRO)
In 2003, the WHO Region for the Western Pacific and Asia
developed a workplan in support of harm reduction that
embraced HIV/AIDS prevention, care, support and treat-
ment for PWID. It was based on assessment missions to
countries with varied situations with regard to HIV and
the use of drugs including China, Cambodia, Lao PDR,
Malaysia and Viet Nam. Consultations were also held also
with key partners in this area, including UNAIDS,
UNODC, CDC-Global AIDS Program, Family Health
International (FHI) and Burnet Center for Harm Reduc-
tion. The framework used reflects WHO's overall manage-
ment plan and expected results: to develop tools and
guidelines; to strengthen country capacity; and to provide
regional support for country programme development.
One of the expected results was the development of tools
and guidelines:
(1) A publication entitled Drug dependence detoxification
and treatment guidelines for low-resource, high HIV-risk set-
tings. These protocols and associated training packages
have been developed as a joint initiative with the Austral-
ian National Drug and Alcohol Research Centre, one of
the WHO Collaborating Centres. The package is being
field-tested in Cambodia in the second semester of 2008.
A final version will be published by the end of 2008.
(2) A manual on HIV/AIDS care and treatment for people
who inject drugs was published in March 2008.
(3) HIV testing and counselling in settings attended by people
who inject drugs is scheduled for publication in 2008.
These tools and guidelines will be extremely helpful for
Members States and civil society to further develop harm
reduction strategies in the Region.
(4) A revised framework to address TB-HIV Co-Infection
in the Western Pacific Region, was launched in July of
2008 and dedicated one chapter for TB-HIV in Closed Set-
tings and among people who inject drugs.
A second main task from the workplan is to give support
to Member States. It is important to state that HIV Pro-
grammes in WHO country offices in the region count with
a focal person for Harm Reduction in the six mentioned
countries. Their contribution is being crucial. Consistency
and technical back-up for the work of WHO country
offices in the Region is provided by WPRO. The HIV/STI
Focus Unit of WPRO had an important role to play in the
achievements made by the six countries discussed in this
paper.
The third main task is to provide regional support. A
standing participation in the UN Regional Task Force has
been an important contribution from WHO to a collective
effort. WPRO is also working hard to develop regional
alliances with crucial partners (UNODC, UNAIDS,Harm Reduction Journal 2008, 5:26 http://www.harmreductionjournal.com/content/5/1/26
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UNICEF, DFID, AusAID, SIDA, WHO/SEARO, Interna-
tional Network of People Using Drugs [INPUD], and oth-
ers) for better development of harm reduction strategies
to tackle the epidemics in the Region. Together with
UNODC, WPRO will organize a meeting during the 20th
International Harm Reduction Conference in Bangkok, in
2009, of all the relevant community-based organizations
in the field of drug use. WPRO is also collaborating with
the Australian National Council on Drugs and the Burnet
Institute to better develop a network on drug research in
the Pacific Area, almost unexplored in terms of the health
consequences of the misuse of illegal drugs.
At present, the main objectives of the WPRO HIV/AIDS
and STI Unit in the field of harm reduction are to harmo-
nize (as much as possible) the response to the HIV/AIDS
epidemics among PWID in different countries of the
Region; help countries to develop better policies, legisla-
tions and practices to facilitate their response; increase the
availability of advocacy tools; reinforce the main package
of interventions comprising NSP, Drug Dependence
Treatment (mostly but not only OST) and care, support
and treatment (including ARV). Co-infections of TB and
Hepatitis C are also being addressed. WHO is in a privi-
leged position among the UN agencies to be the interloc-
utor with the health sector, supported by science,
evidence-based results and political will. WHO also has
the technical expertise to take the lead in helping to pro-
mote the changes needed to adequately face the epidemic
among and from people who inject drugs.
Conclusion
Injecting drug use is driving HIV epidemics in many coun-
tries and accounts for almost a third of new infections out-
side sub-Saharan Africa [3]. Across the estimated 13
million PWID globally, drug use patterns, behaviours and
contexts vary widely [78]. The common thread that runs
through all epidemic situations in the Asia-Pacific region
is that the major HIV risk behaviour groups affected
(PWID, MSM, sex workers and their clients) are socially
marginalized and engage in socially unacceptable and
often illegal behaviours [22]. Many countries in Asia face
difficult public policy and legislative problems with
regard to sex work, homosexuality and drug use. In addi-
tion, widespread poverty, and a general lack of access to
effective health and welfare services by the poor and dis-
advantaged in both rural and urban areas, means that the
challenges of developing targeted intervention pro-
grammes, and ensuring coverage of vulnerable groups, are
particularly acute. Attention to these challenges is urgently
required [78]. Supportive policies, including policies that
ensure equitable access to HIV services for drug users; a
conducive legal and social environment; laws that do not
compromise access to HIV services for drug users through
criminalization and marginalization; and campaigns to
reduce stigma and discrimination, are needed to combat
the epidemics [78]. Until there is full public and policy-
maker acceptance of the need to develop and expand
effective risk behaviour change, and reduction or elimina-
tion programmes, HIV will continue to spread in the Asia-
Pacific region [21].
In conjunction with many other partners, WHO pioneers
the promotion and development of evidence-based strat-
egies for harm reduction in the Region. Because of the
efforts made, harm reduction is no longer a marginal strat-
egy in the Region. While the progress made has been
impressive, it is important to consolidate the advances
and scale up interventions to better confront the epidem-
ics driven by injecting drug use.
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